ClinicalTrials.gg
Active, not recruitingNCT04612751TROPION-Lung04Updated Oct 27, 2026

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 1 interventional study of Datopotamab deruxtecan and Durvalumab in Advanced or Metastatic NSCLC, sponsored by AstraZeneca. Active, not recruiting at 42 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
155
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
14th of 21
155 · median 278
Started
2021
with 2 others
Phase 1
3 of 21
none open now
Primary completion
2026-05
later than 4 of 18 live
Registered
5th of 21
by date
Lead sponsor
11 of 21
AstraZeneca

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 1, reaches primary completion later than 4 of the 18 other live ones, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Read the detailed description

The primary objective is to assess the safety and tolerability of Dato-DXd in combination with immunotherapy with or without 4 cycles of carboplatin in participants with advanced or metastatic NSCLC.

Two dose levels of Dato-DXd will be studied in combination with immunotherapy (durvalumab, AZD2936, MEDI5752, or AZD7789) with or without 4 cycles of carboplatin in 15 study cohorts

Each cohort will start with Part 1 (dose escalation or confirmation), where 3 to 9 participants will be assessed for dose-limiting toxicities (DLT) in the first cycle of treatment. if the DLT incidence rate meets the criteria based on the modified toxicity probability interval-2 (mTPI-2), then Part 2 (dose expansion) may be opened.

03

Conditions studied

  • Advanced or Metastatic NSCLC

Keywords

  • Advanced or Metastatic NSCLC
  • Datopotamab deruxtecan (Dato-DXd)
  • DS-1062a
  • Durvalumab
  • AZD2936
  • MEDI5752
  • AZD7789
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant ≥18 years old on the day of signing the ICF (local regulatory requirement to consent should be followed).
  • or cytologically confirmed diagnosis of advanced or NSCLC, without EGFR or ALK genomic alterations (testing not required for participants with documented squamous histology) and no known genomic alterations in other actionable driver kinases with approved therapies. Participants whose tumors harbor KRAS mutations are eligible for this study.
  • For Cohorts 1 to 4, participants must be treatment-naïve or have received and radiologically progressed after only 1 , without concomitant for advanced or metastatic NSCLC. For Cohorts 4a, 5 to 11, and 14, participants must be treatment-naïve for advanced or metastatic NSCLC. For Cohorts 12 to 13, participants must be CPI acquired resistant after 1 or 2 prior lines of systemic therapy for advanced or metastatic NSCLC, of which 1 should have contained an approved anti-PD-1/PD L1. Cohort 4a will enroll participants whose tumors have squamous histology only; Cohorts 5 Part 2A and Part 2B as well as Cohorts 12 and 13 will enroll participants whose tumors have non-squamous histology only.
  • Willing and able to undergo a mandatory tumor . A tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen may be substituted for the biopsy collected during screening. For Cohorts 12 and 13, a tumor sample taken ≤24 months prior to screening is acceptable.
  • Has per RECIST1.1 within 28 days prior to Cycle 1 Day 1
  • Eastern Co-operative Oncology Group () performance status of 0 or 1 at screening
  • Has adequate bone marrow reserve and organ function at baseline within 7 days prior to Cycle 1 day 1
  • For Cohorts 5 to 14 only: Documented IHC PD-L1 expression per analytically validated Ventana PD-L1 (SP263) IHC assay, 22C3 PharmDx assay, or 28-8 PharmDx assay

Exclusion criteria

Exclusion Criteria:

  • Active or prior documented or inflammatory disorders
  • Uncontrolled or significant cardiac disease
  • History of another primary with exceptions
  • active or uncontrolled or C virus or uncontrolled infection
  • spinal cord compression or clinically active
  • History of (non-infectious) ILD/pneumonitis that required
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illness
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • corneal disease
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy

    Drug: Datopotamab deruxtecan · Drug: Durvalumab

  • Experimental
    Cohort 2

    Datopotamab deruxtecan (Dato-DXd) + Durvalumab in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy

    Drug: Datopotamab deruxtecan · Drug: Durvalumab

  • Experimental
    Cohort 3

    Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy

    Drug: Datopotamab deruxtecan · Drug: Durvalumab · Drug: Carboplatin

  • Experimental
    Cohort 4

    Datopotamab deruxtecan (Dato-DXd) + Durvalumab + Carboplatin in NSCLC participants who are either treatment-naïve or have received only 1 prior line of systemic chemotherapy without concomitant ICI therapy

    Drug: Datopotamab deruxtecan · Drug: Durvalumab · Drug: Carboplatin

  • Experimental
    Cohort 5

    Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: AZD2936

  • Experimental
    Cohort 6

    Datopotamab deruxtecan (Dato-DXd) + AZD2936 in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: AZD2936

  • Experimental
    Cohort 7

    Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: Carboplatin · Drug: AZD2936

  • Experimental
    Cohort 8

    Datopotamab deruxtecan (Dato-DXd) + AZD2936 + Carboplatin in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: Carboplatin · Drug: AZD2936

  • Experimental
    Cohort 9

    Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: Carboplatin · Drug: MEDI5752

  • Experimental
    Cohort 10

    Datopotamab deruxtecan (Dato-DXd) + MEDI5752 + Carboplatin in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: Carboplatin · Drug: MEDI5752

  • Experimental
    Cohort 11

    Datopotamab deruxtecan (Dato-DXd) + MEDI5752 in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: MEDI5752

  • Experimental
    Cohort 12

    Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC

    Drug: Datopotamab deruxtecan · Drug: AZD7789

  • Experimental
    Cohort 13

    Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with CPI acquired resistant NSCLC

    Drug: Datopotamab deruxtecan · Drug: AZD7789

  • Experimental
    Cohort 14

    Datopotamab deruxtecan (Dato-DXd) + AZD7789 in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: AZD7789

  • Experimental
    Cohort 4A

    Datopotamab deruxtecan (Dato-DXd) + Durvalumab + carboplatin in participants with treatment-naïve NSCLC

    Drug: Datopotamab deruxtecan · Drug: Durvalumab · Drug: Carboplatin

Interventions

  • Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

    Also known as: Dato-DXd

  • Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

    Also known as: Imfinzi

  • Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

  • Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

    Also known as: rilvegostomig

  • Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

    Also known as: volrustomig

  • DrugAZD7789

    Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

    Also known as: sabestomig

06

What researchers measure

Primary outcomes

  1. Number of participants with DLTs; TEAEs and other safety parameters during the study.

    DLTs, TEAEs, SAEs, AESIs, ECOG PS, vital sign measurements, standard clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), ECG parameters, ECHO/MUGA scan findings, and ophthalmologic findings

    Time frame: DLTs: within first cycle (21 days); TEAEs and other safety parameters: when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up (approximately 60 months)

Secondary outcomes

  1. ORR as assessed by investigator per RECIST Version 1.1

    ORR is defined as the proportion of participants with measurable disease at baseline who achieved a BOR of confirmed CR or confirmed PR.

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  2. Duration of Response as assessed by investigator per RECIST version 1.1

    Duration of Response is defined as the time from the date of the first documentation of objective response (confirmed CR or confirmed PR) to the date of the first documentation of objective PD, or death due to any cause, whichever occurs first.

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  3. Disease Control Rate as assessed by the investigator per RECIST version 1.1

    Disease Control Rate is defined as the proportion of participants who achieved a Best Overall Response of confirmed complete response, confirmed partial response, or stable disease.

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  4. Progression-free Survival as assessed by the investigator per RECIST v1.1

    Progression-free Survival is defined as the time interval from the date of the start of study treatment to the earlier of the dates of the first documentation of objective PD or death due to any cause, whichever occurs first

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  5. Time to Response as assessed by investigator per RECIST Version 1.1

    Time to Response is defined as the time from the date of the start of study treatment to the date of the first documentation of objective response (confirmed complete response or confirmed partial response)

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  6. Best percentage change in the Sum of Diameters of measurable tumors

    The best percentage change in the Sum of Diameters of measurable tumors is defined as the percentage change in the smallest Sum of Diameters from all postbaseline tumor assessments, taking as reference the baseline Sum of Diameters.

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  7. Overall Survival

    Overall Survival is defined as the time from the date of the start of study treatment to the date of death due to any cause

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  8. Pharmacokinetic Parameter Maximum Plasma/Serum Concentration (Cmax) of Dato-DXd, Total anti-TROP2 antibody, and MAAA-1181a. Serum concentrations of durvalumab and MEDI5752, AZD2936, MEDI5752 and AZD7789.

    Cmax = Maximum concentration

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  9. Pharmacokinetic Parameter Time to Maximum Plasma/Serum Concentration (Tmax) of Dato-DXd, Total anti-TROP2 antibody, and MAAA-1181a.

    Tmax = time to reach maximum concentration.

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  10. Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve (AUC) of Dato-DXd, Total anti-TROP2 antibody, and MAAA-1181a.

    Area under the plasma concentration-time curve up to last quantifiable time (AUClast) and area under the plasma concentration-time curve during dosing interval (AUCtau) will be assessed.

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  11. Prevalence of Dato-Dxd, durvalumab, AZD2936, MEDI5752 and AZD7789 ADA

    ADA prevalence is defined as the proportion of all participants having ADA at any point in time (including pre-existing ADA at baseline and treatment-emergent ADA)

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

  12. Incidence of Dato-DXd, durvalumab, AZD2936, MEDI5752 and AZD7789 ADA

    ADA incidence is defined as the proportion of participants having treatment-emergent ADA during the study period

    Time frame: At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).

07

Study locations

42 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Santa Ana, California 92705, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Aviano, 33081, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Lodz, 93-338, Poland
  • Research Site
    Lublin, 20-090, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    A Coruña, 15005, Spain
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 8036, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Seville, 41015, Spain
  • Research Site
    Hsinchu, 300, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taipei, 110, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 00333, Taiwan
  • Research Site
    Adana, 01060, Turkey (Türkiye)
  • Research Site
    Ankara, 06800, Turkey (Türkiye)
  • Research Site
    Ankara, 6200, Turkey (Türkiye)
  • Research Site
    Istanbul, 34010, Turkey (Türkiye)
  • Research Site
    Izmir, 35330, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2026, 63 months.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 63 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Nov 3, 2020
StartActual
Feb 2, 2021
Primary completionActual
May 4, 2026
CompletionEst.
May 4, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04612751
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Feb 2, 2021
Primary completion
May 4, 2026
Completion
May 4, 2027 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Datopotamab deruxtecan · Carboplatin

Start the discussion